JP2011529084A - アミロイドβペプチド類似体、これらのオリゴマー、前記類似体またはオリゴマーを調製するためのプロセスおよび前記類似体またはオリゴマーを含む組成物ならびにこれらの使用 - Google Patents

アミロイドβペプチド類似体、これらのオリゴマー、前記類似体またはオリゴマーを調製するためのプロセスおよび前記類似体またはオリゴマーを含む組成物ならびにこれらの使用 Download PDF

Info

Publication number
JP2011529084A
JP2011529084A JP2011520233A JP2011520233A JP2011529084A JP 2011529084 A JP2011529084 A JP 2011529084A JP 2011520233 A JP2011520233 A JP 2011520233A JP 2011520233 A JP2011520233 A JP 2011520233A JP 2011529084 A JP2011529084 A JP 2011529084A
Authority
JP
Japan
Prior art keywords
amino acid
sequence
acid residue
amyloid
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011520233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011529084A5 (cg-RX-API-DMAC7.html
Inventor
バルクホルン，シユテフアン
ヒレン，ハインツ
エダルジ，ロヒントン
バレツト，レオ
リチヤードソン，ポール
ユイ，リーピン
オレイニチヤク，エドワード
ハーラン，ジヨン
ホルツマン，トーマス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2011529084A publication Critical patent/JP2011529084A/ja
Publication of JP2011529084A5 publication Critical patent/JP2011529084A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2011520233A 2008-07-25 2009-07-24 アミロイドβペプチド類似体、これらのオリゴマー、前記類似体またはオリゴマーを調製するためのプロセスおよび前記類似体またはオリゴマーを含む組成物ならびにこれらの使用 Pending JP2011529084A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8358908P 2008-07-25 2008-07-25
US61/083,589 2008-07-25
PCT/US2009/051721 WO2010011947A2 (en) 2008-07-25 2009-07-24 AMYLOID ß PEPTIDE ANALOGUES, OLIGOMERS THEREOF, PROCESSES FOR PREPARING AND COMPOSITIONS COMPRISING SAID ANALOGUES OR OLIGOMERS, AND THEIR USES

Publications (2)

Publication Number Publication Date
JP2011529084A true JP2011529084A (ja) 2011-12-01
JP2011529084A5 JP2011529084A5 (cg-RX-API-DMAC7.html) 2012-05-31

Family

ID=41570887

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011520233A Pending JP2011529084A (ja) 2008-07-25 2009-07-24 アミロイドβペプチド類似体、これらのオリゴマー、前記類似体またはオリゴマーを調製するためのプロセスおよび前記類似体またはオリゴマーを含む組成物ならびにこれらの使用

Country Status (7)

Country Link
US (1) US20110092445A1 (cg-RX-API-DMAC7.html)
EP (1) EP2303920A4 (cg-RX-API-DMAC7.html)
JP (1) JP2011529084A (cg-RX-API-DMAC7.html)
CN (1) CN102203124A (cg-RX-API-DMAC7.html)
CA (1) CA2730804A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011000975A (cg-RX-API-DMAC7.html)
WO (1) WO2010011947A2 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505391A (ja) * 2012-10-27 2016-02-25 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 基板上にナノ多孔性層を製造する方法
JP2017532289A (ja) * 2014-07-07 2017-11-02 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
JP2021123551A (ja) * 2020-02-04 2021-08-30 国立大学法人京都大学 アミロイドβ４２架橋アナログペプチド

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PT1954718E (pt) 2005-11-30 2014-12-16 Abbvie Inc Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2262526B1 (en) * 2008-04-14 2015-12-02 Alzinova AB Stable amyloid beta monomers and oligomers
AU2009266552B2 (en) * 2008-07-01 2014-01-23 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Vaccine against amyloid folding intermediate
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
MX341536B (es) * 2010-03-03 2016-08-24 The Univ Of British Columbia * Epitopo y anticuerpos beta amiloide de oligomero especifico.
AU2013205000B2 (en) * 2010-03-03 2015-05-28 The University Of British Columbia Oligomer-specific amyloid beta epitope and antibodies
CN102933601B (zh) 2010-04-15 2016-06-08 Abbvie公司 β淀粉样蛋白结合蛋白
US9364449B2 (en) 2010-06-09 2016-06-14 New York University Peptoid and synthetic oligomers, pharmaceutical compositions and methods of using same
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
US20120089291A1 (en) * 2010-10-12 2012-04-12 Halder Bibhrajit Autonomous machine control system
US11231426B2 (en) 2010-11-29 2022-01-25 Inven2 As Methods and compositions for monitoring phagocytic activity
WO2012072611A1 (de) * 2010-11-29 2012-06-07 Philipps-Universität Marburg SYNTHETISCHE LIGANDEN FÜR HUMANE ANTI-Aβ-ANTIKÖRPER
JP6220344B2 (ja) * 2011-11-29 2017-10-25 プロクララ バイオサイエンシーズ， インコーポレイテッド アミロイド結合剤としてのバクテリオファージのｐ３の使用
US20130164217A1 (en) * 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
EP2746402A1 (en) * 2013-03-12 2014-06-25 Academisch Medisch Centrum Method of prognosis of Alzheimers disease and substrates for use therein
EP2787349A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting proteinopathy-specific antibodies in a biological sample
EP2787347A1 (en) * 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
KR102331422B1 (ko) 2014-01-31 2021-11-25 카그니션 테라퓨틱스, 인코퍼레이티드 아이소인돌린 조성물 및 신경퇴행성 질환을 치료하는 방법
JP6675403B2 (ja) * 2014-09-05 2020-04-01 システム オブ システムズ アナリティクス インコーポレイテッド アミロイドベータオリゴマーを検出する方法
ES2571055B1 (es) * 2016-02-15 2016-12-28 Araclon Biotech, S.L. Conjugado amiloide y usos y procedimientos del mismo
WO2018005980A1 (en) * 2016-07-01 2018-01-04 The Scripps Research Institute Compositions and diagnostic methods related to transthyretin amyloid diseases
US11214540B2 (en) 2017-05-15 2022-01-04 Cognition Therapeutics, Inc. Compositions for treating neurodegenerative diseases
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CN108148115A (zh) * 2018-01-30 2018-06-12 中国药科大学 一种环肽合成新方法及其在药物开发中的应用
US20210262006A1 (en) * 2018-06-18 2021-08-26 Emory University Parallel Enzyme Digestion for Protein Biomarker Detection
CN109912687A (zh) * 2019-03-20 2019-06-21 横琴欣健生物科技研究院有限公司 一种治疗老年痴呆症的多肽药物
CN109851660A (zh) * 2019-03-20 2019-06-07 横琴欣健生物科技研究院有限公司 一种治疗老年痴呆症的多肽及其疫苗
KR102767892B1 (ko) * 2021-12-30 2025-02-14 고려대학교 산학협력단 신규한 단백질 변이체 및 이를 이용한 신경퇴행성 질환 치료용 조성물
US12037375B2 (en) * 2021-12-30 2024-07-16 Korea University Research And Business Foundation Protein variant and composition for treating neurodegenerative disease using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750349A (en) * 1993-01-25 1998-05-12 Takeda Chemical Industries Ltd. Antibodies to β-amyloids or their derivatives and use thereof
DE10101430B4 (de) * 2001-01-13 2008-10-02 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Lösliche cyclische Analoga zur Modulation der Amyloidogenese
US20020132758A1 (en) * 2001-01-18 2002-09-19 Shell John W. Method for identifying compounds to treat medical pathologies associated with molecular crystallization
US20070213512A1 (en) * 2002-10-01 2007-09-13 Krafft Grant A Amyloid beta peptide analogs and assemblies thereof
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1676859A1 (en) * 2004-12-30 2006-07-05 Pevion Biotech Ltd. Immunogenic compositions of cyclic peptides derived from the beta-amyloid peptide
CN101365717A (zh) * 2005-03-05 2009-02-11 艾博特股份有限两合公司 筛选方法、纯化非扩散A-β寡聚体的方法、抗所述非扩散A-β寡聚体的选择性抗体以及制备所述抗体的方法
WO2007064917A2 (en) * 2005-11-30 2007-06-07 Abbott Laboratories Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins
DK2091948T3 (da) * 2006-11-30 2012-07-23 Probiodrug Ag Nye inhibitorer af glutaminylcyclase

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016505391A (ja) * 2012-10-27 2016-02-25 フォルシュングスツェントルム・ユーリッヒ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 基板上にナノ多孔性層を製造する方法
JP2017532289A (ja) * 2014-07-07 2017-11-02 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
JP2021001203A (ja) * 2014-07-07 2021-01-07 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
JP2023036606A (ja) * 2014-07-07 2023-03-14 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
JP2021123551A (ja) * 2020-02-04 2021-08-30 国立大学法人京都大学 アミロイドβ４２架橋アナログペプチド
JP7357354B2 (ja) 2020-02-04 2023-10-06 国立大学法人京都大学 アミロイドβ４２架橋アナログペプチド

Also Published As

Publication number Publication date
WO2010011947A2 (en) 2010-01-28
US20110092445A1 (en) 2011-04-21
MX2011000975A (es) 2011-05-25
EP2303920A4 (en) 2011-11-09
CN102203124A (zh) 2011-09-28
EP2303920A2 (en) 2011-04-06
CA2730804A1 (en) 2010-01-28
WO2010011947A3 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
JP2011529084A (ja) アミロイドβペプチド類似体、これらのオリゴマー、前記類似体またはオリゴマーを調製するためのプロセスおよび前記類似体またはオリゴマーを含む組成物ならびにこれらの使用
CA2514582C (en) Amyloid-.beta.(1-42) oligomers, derivatives thereof, antibodies for the same, method for production and use thereof
JP2023036606A (ja) 突然変異タンパク質アミロイドβ（Ａβ）アミノ酸配列に基づく免疫原性産物およびその使用
JP5722770B2 (ja) アミロイド折りたたみ中間体に対するワクチン
JP4709149B2 (ja) プリオン特異的ペプチド試薬
US20060025575A1 (en) Immunological detection of prions
WO2010010469A2 (en) Abeta (x-38..43) oligomers, and processes, compositions, and uses thereof
JP2000516572A (ja) プリオンタンパク質に結合し、イソ型ＰｒＰ▲上ｃ▼とＰｒＰ▲上ｓｃ▼を識別することが可能なシャペロン
US11319348B2 (en) Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
JP4079775B2 (ja) β−アミロイドペプチドの可溶性環状類似体
JP2008543791A (ja) Ｐｓｐ９４診断薬およびアッセイ
AU2003288434B2 (en) Peptides, antibodies thereto, and their use in the treatment of central nervous system damage
US20060057636A1 (en) Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20090099343A1 (en) Isolation of pathogenic prions
US20090191571A1 (en) Isolation and Detection of Pathogenic Prions
WO1999046574A2 (en) Antibodies for assessing protein post-translational modification status and methods of making and using the same
Oboznaya et al. Production of monoclonal antibodies to the prion protein and their characterization
BR112017000428B1 (pt) Produto imunogênico com base em sequências de aminoácidos muteína amiloide beta, composição compreendendo o produto e uso do mesmo para tratar ou prevenir amiloidose

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120404

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120404

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20130701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130822

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131203

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140603